Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Zhuangbo, Mou"'
Autor:
Fei Kong, Hong Qin, Jidong Jia, Yujuan Guan, Yanhua Ding, Hai Pan, Yongfeng Yang, Qing Mao, Zhiliang Gao, Xiaozhong Wang, Chenghao Li, Qin Ning, Sujun Zheng, Desheng Zhou, Guicheng Wu, Xiaofeng Wen, Li Li, Zhuangbo Mou, Guangming Li, Jinghua Hu, Xiaofeng Wu, Huichun Xing, Jing Ning, Cheng Li, Junqi Niu, Zhansheng Jia, Jianmei Lin, Yanhang Gao
Publikováno v:
Liver International
Background & Aim An affordable, pangenotypic regimen remains as an unmet medical need for chronic hepatitis C patients in China. This single‐arm, open‐label, multicenter, phase 3 trial evaluated the efficacy and safety of coblopasvir, a pangenoty
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::041a9a30fa107e5f498324ff3fb9c644
http://europepmc.org/articles/PMC7702130
http://europepmc.org/articles/PMC7702130
Autor:
Jin Lin Hou, Feng Lin, Lai Wei, Luisa M. Stamm, Yanhang Gao, Qin Ning, Seng Gee Lim, Sophia Lu, Peng Hu, Jidong Jia, Kinh Nguyen Van, Zhuangbo Mou, Abhasnee Sobhonslidsuk, Ming Xu, Teerha Piratvisuth, Minghua Su, Hoi Poh Tee, Guozhong Gong, Satawat Thongsawat, Guiqiang Wang, Lunli Zhang, Rosmawati Mohamed, Shanming Wu, Zhi Liang Gao, Jia Shang, Hongmei Mo, Hung Le Manh, Jun Cheng, Diana M. Brainard, Qing Xie, Yongfeng Yang, Long Dao, Xiaguang Dou, Hadas Dvory-Sobol, Zhongping Duan, Thi Tuyet Phuong Le, Pisit Tangkijvanich, Yan Huang, Hong Tang, Tawesak Tanwandee, Jun Li, Yuemin Nan, Yimin Mao, Chee-Kiat Tan
Publikováno v:
The Lancet Gastroenterology & Hepatology. 4:127-134
Summary Background Treatment with combined sofosbuvir and velpatasvir has resulted in high sustained virological response rates in patients chronically infected with hepatitis C virus (HCV) with genotypes 1–6 in clinical trials and real-world setti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16deead8947d036b7f65eab87a163c5d
https://doi.org/10.1016/s2468-1253(18)30343-1
https://doi.org/10.1016/s2468-1253(18)30343-1
Autor:
Jun Cheng, Hong Tang, Lai Wei, Qin Ning, Shanming Wu, Jin Lin Hou, Gregory Camus, Diana M. Brainard, Qing Xie, Brian McNabb, Jidong Jia, Yuemin Nan, Peng Hu, Guozhong Gong, Guiqiang Wang, Jianning Jiang, Fangqiu Zhang, Zhuangbo Mou, Jun Li, Zhongping Duan, Anu Osinusi, Yanhang Gao, Lunli Zhang, Hongmei Mo
Publikováno v:
Hepatology International
Background Chronic hepatitis C virus (HCV) infection is a significant medical burden in China, affecting more than 10 million persons. In clinical trials and real-world settings, treatment with ledipasvir/sofosbuvir in patients with genotype 1 HCV in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31bf2cddb23e441b93b874b2aa0f116c
http://europepmc.org/articles/PMC5904238
http://europepmc.org/articles/PMC5904238
Autor:
Zhuangbo Mou, Jun Li, Qin Ning, Jun Qi Niu, Deyuan Jiang, Steven J. Knox, Shanming Wu, Polina German, Jianning Jiang, Wu Li, Yuemin Nan, Zhi Liang Gao, Zhongping Duan, Guiqiang Wang, Kathryn Kersey, Jin Lin Hou, Lun Li Zhang, Jenny C. Yang, Yongfeng Yang, Benedetta Massetto, Hong Tang, Lai Wei, Jun Cheng, Feng Lin, Peng Hu, Xiaoguang Dou, Min Xu, Qing Xie, Diana M. Brainard, Guozhong Gong, Jidong Jia, Lanjuan Li, Hongmei Mo, Jiaji Jiang
Publikováno v:
Journal of Gastroenterology and Hepatology. 33:1168-1176
BACKGROUND AND AIM Sofosbuvir is a nucleotide analog inhibitor of the hepatitis C virus (HCV) NS5B RNA polymerase with pangenotypic potency. This phase 3b study evaluated the safety and efficacy of sofosbuvir + ribavirin ± peginterferon in Chinese p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64dfe8967a57a556adf872ff56712514
https://doi.org/10.1111/jgh.14102
https://doi.org/10.1111/jgh.14102
Autor:
Qing Xie, Jun Cheng, Qin Ning, Tawesak Tanwandee, Hoi Poh Tee, Seng Gee Lim, Zhuangbo Mou, Abhasnee Sobhonslidsuk, Ming Xu, Jun Li, Yuemin Nan, Zhi Liang Gao, Yongfeng Yang, Hong Tang, Jin Lin Hou, Guiqiang Wang, Teerha Piratvisuth, Guozhong Gong, Minghua Su, Sophia Lu, Shanming Wu, Thi Tuyet Phuong Le, Yimin Mao, Chee-Kiat Tan, Hadas Dvory-Sobol, Hung Le Manh, Yan Huang, Yanhang Gao, Rosmawati Mohamed, Lai Wei, Jia Shang, L.M. Stamm, Kinh Nguyen Van, Pisit Tangkijvanich, Lunli Zhang, Hongmei Mo, Xiaguang Dou, Zhongping Duan, Long Dao, Peng Hu, Satawat Thongsawat, Diana M. Brainard, Jidong Jia, Feng Lin
Publikováno v:
SSRN Electronic Journal.
Background: Treatment with sofosbuvir/velpatasvir has resulted in high sustained virologic response rates in HCV-infected patients with genotype 1 to 6 in clinical trials and real-world settings, but its efficacy and safety has not been assessed in A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5f527a9514bec88f483757a2c974f15f
https://doi.org/10.2139/ssrn.3255830
https://doi.org/10.2139/ssrn.3255830
Autor:
Lai, Wei, Qing, Xie, Jin Lin, Hou, Jidong, Jia, Wu, Li, Min, Xu, Jun, Li, Shanming, Wu, Jun, Cheng, Jianning, Jiang, Guiqiang, Wang, Yongfeng, Yang, Zhuangbo, Mou, Zhi Liang, Gao, Guozhong, Gong, Jun Qi, Niu, Peng, Hu, Hong, Tang, Feng, Lin, Xiaoguang, Dou, Lanjuan, Li, Lun Li, Zhang, Yuemin, Nan, Benedetta, Massetto, Jenny C, Yang, Steven J, Knox, Kathryn, Kersey, Polina, German, Hongmei, Mo, Deyuan, Jiang, Diana M, Brainard, Jiaji, Jiang, Qin, Ning, Zhongping, Duan
Publikováno v:
Journal of gastroenterology and hepatology. 33(6)
Sofosbuvir is a nucleotide analog inhibitor of the hepatitis C virus (HCV) NS5B RNA polymerase with pangenotypic potency. This phase 3b study evaluated the safety and efficacy of sofosbuvir + ribavirin ± peginterferon in Chinese patients infected wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c375ff7c483472b6199695e64f30c1ad
https://pubmed.ncbi.nlm.nih.gov/29998515
https://pubmed.ncbi.nlm.nih.gov/29998515